Message from Chairman

The history of Tianjin Institute of Pharmaceutical Research (TIPR) for more than 60 years is the epitome of the development of new China’s pharmaceutical industry. As time goes on, TIPR has become an important member in the health industry of China Merchants Group, and is still flourishing, walking more and more firmly and confidently on the road of pharmaceutical innovation.

Innovation is the spirit of Tianjin Institute of Pharmaceutical Research. From the “Tri-element one sulfonamide”, which filled the gap of Chinese medicine, to the first dripping pills “Suxiao Jiuxin Pill”, the first soft capsule preparation “Maren Soft Capsules”, the first Class II new drug “Indapamide”, and the exclusive product “Agatroban” and “Adefovir”, more than 200 new drug certificates are the achievements of the continuous pursuit of innovation by the generations of TIPR.

Reform is the main line of innovation and development of Tianjin Institute of Pharmaceutical Research. The development of TIPR experienced three important stages, from a central government-affiliated institution, to a state-owned enterprise in Tianjin, to a mixed-ownership enterprise belonging to a central enterprise. TIPR has blazed a development path with its own distinctive characteristics by keeping innovation according to the development of the times.

Struggle is the heritage of the enterprise spirit of TIPR. “Revitalizing the pharmacy through science and technology is for the good of all mankind” is the original intention and mission of TIPR, and it is the responsibility and motivation for generations of scientists and technicians to make continuous progress in scientific and innovative achievements. Contributing new drugs and good drugs to the society and applying the technology and products to the motherland is the greatest value we can achieve.

Entering a new era and standing at a new starting point, Tianjin Institute of Pharmaceutical Research  reinvigorated to achieve the dream of “A hundred years of TIPR, international TIPR” and to help achieve a strong pharmaceutical country and a healthy China!

Company Profile

Tianjin Institute of Pharmaceutical Research (TIPR), as one of the nation’s most important institutes, has a history of over half a century and has been engaged in pharmaceutical research and development. Today it has grown from an academic research institute up to a comprehensive high-tech pharmaceutical enterprise integrating scientific research, manufacture and sales. The scientific research of TIPR covers the fields of drug synthesis, pharmaceutical preparations, Chinese medicine pharmacy, modern biological pharmaceutical, pharmacological drug, drug safety evaluation, drug analysis and medical information. With advanced talents and relying on the State Key Laboratory as well as other professional platforms, TIPR pays special attention to the engineering and industrialization of new technology. Meanwhile it meets all kinds of new drug registration requirements. Its technologies in the fields of drug metabolism and pharmacokinetics, safety evaluation and new preparation are in the leading positions in China.

TIPR possesses independent industrial and technical service platforms to promote the transfer of research achievements. We are composed of TIPR Pharmaceutical Co., Ltd.(holding controlled) , TIPR Drug Assessment Co., Ltd. (holding controlled), TIPR-HUYA AIM Co., Ltd. and other pharmaceutical enterprises. For over 50 years, TIPR has carried out fruitful cooperation with pharmaceutical companies all over the country, which not only provides a large number of excellent new medicinal products for the society, but also produces many outstanding enterprises.

With a comprehensive research mechanism and a professional talent team, TIPR has been continuously offering new products and technologies by maintaining close observation of the changes and trends of the pharmaceutical industry. In addition to developing new and excellent pharmaceutical products, TIPR has also brought generous economic returns to our partners. With our comprehensive and professional technical service, TIPR is committed to promoting the upgrading of your products and making your dream come true.

History

1959 – Tianjin Institute of Pharmaceutical Research was set up.

1987 – Three predecessor units converged into Tianjin Institute of Pharmaceutical Research.

2000 – Tianjin Institute of Pharmaceutical Research received localized management from an institution to an enterprise owned by the whole people.

2018 – another important time node in the development history of Tianjin Institute of Pharmaceutical Research. Taking the historical opportunity of mixed-ownership reform, Tianjin Institute of Pharmaceutical Research took the initiative to reform and became an important platform of China Merchants Group in the health industry. Tianjin Institute of Pharmaceutical Research is committed to creating the “world’s influential and China’s first-class” R&D-based pharmaceutical enterprises and becoming a “centennial world institute”.

Corporate Culture

Corporate vision: To become a top R & D pharmaceutical company in China with world influence

Corporate mission: Benefit the medical industry and the mankind with science and technology

Core values: Share your destiny with the motherland and develop with the times

Enterprise spirit: Integrity  Friendliness  Innovation  Dedication

Enterprise philosophy: People-first and equal attention to research and business

Cultural atmosphere: Simple  Sunny  Solerant

Scientists

Chang-xiao LIU, honorary president of Tianjin Institute of Pharmaceutical Research (TIPR) 

Prof. Changxiao LIU, Fellow of Chinese Academy of Engineering. Prof. Liu graduated from Beijing Medical School (also known as Medical Department of Peking University) in 1965. Shortly after graduation, he joined Beijing Institute of Pharmaceutical Sciences. He worked as visiting scholar at Lunds Universitet (English: Lund University, Sweden) during 1986-1987 and was promoted to Professor at early of 1990s. Prof. Liu is the tenured chief scientist, and currently the honorary president of TIPR, also chairs the academic committee of Tianjn Institute of Pharmaceutical Research and is director of State Key Laboratory of Drug Delivery Technology and Pharmacokinetics. In addition, Prof. LIU acts as advisor of Chinese Pharmacopoeia Commission, executive director of Chinese Pharmaceutical Association, chair of Tianjin Pharmaceutical Society and Tianjin Regulatory Science Society, as well as China office director of ISSX. Prof. LIU has been appointed as guest professor/doctoral supervisor of China Pharmaceutical University, Shenyang Pharmaceutical University, Tianjin University, and other higher education institutes. Prof. LIU was nominated and awarded as “exemplar workers in the prevention and treatment of schistosomiasis in Hunan Province in1978”, “Experts on special allowances of the State Council in 1992”, “Tianjin exemplar worker in 2000”, “National exemplar worker in 2005”, “National outstanding science and technology workers in 2013”, “Hong Kong Bauhinia Medical Achievement Award and Gold Award for Medical Innovation in 2000”, “Thai Medicine Golden Elephant Award in 2000”, “German Medical Paper Award in 2000”, “Special Contribution Award of CPA in 2017”, “Special Contribution Award of ISSX in 2014”, “Life Achievement Award of WTCMS in 2018”, and “Life Achievement Award of Evidence-based TCM in 2020”.

Prof. Liu dedicated his life to pharmacology, particularly in pharmacokinetics field. He established the first specific laboratory for pharmacokinetics study in 1968. In 1975, pharmacokinetics was applied to review and assess new drug by Prof. Liu. The concept of pharmacokinetics was initially introduced to public and academia in China in 1980. In addition, He established the first Provincial Laboratory of pharmacokinetics in 1995 and State Key Laboratory of Pharmacokinetics in 2005. Concept of Model optimization, Automation and Batch processing have been proposed in “Practical program for pharmacokinetics” and been widely applied in pharmacokinetic studies, which has been extensively cited by over 9700 papers and applications up to date.

For the past 50 years, Prof. Liu has published over 400 peer-reviewed papers and 30 academic books. Prof. LIU has completed over 50 basic research projects funded either by central or local authorities, as well as over 150 drug development projects. The team led by Prof. LIU has been awarded over 40 Science and Technology Awards.

Prof. LIU has long been engaged in and dedicated to pharmacokinetics, drug evaluation, modernization of TCM, as well as strategy of biomedication.

Tiejun Zhang, chief expert and researcher of TCM Research and Development Centre in Tianjin Institute of Pharmaceutical Research. Expert with special allowance of the State Council, commissioned expert in Tianjin, national excellent science and technology worker. Member of CPA Specialized Committee on TCM and Natural Medicines; Vice president of WFCMS Professional Committee on New Drug Delivery Systems; Standing committee member of CSNR Professional Committee on Traditional Chinese Medicine Resources; Editorial board member of Acta Pharmaceutica Sinica, and Chinese Traditional and Herbal Drugs.
Engaged in R&D of new TCM, TCM quality control and secondary development of TCM species. Undertook 35 National and Tianjin Science and Technology Projects; Responsible for R&D of more than 20 TCM drugs and won 4 new drug certificates. Won more than 40 national invention patents; Edited 11 academic works, participated in the preparation of 13 works and published more than 300 papers. Won the first prize for scientific progress in National Administration of Traditional Chinese Medicine; Won the First Prize for Scientific and Technological Progress in Tianjin and two Second Prizes for Scientific and Technological Progress in Tianjin; Won First Prize for Scientific and Technological Progress in Anhui Province; Won Third Prize for Science and Technology in CPA.

To be the top R&D engine BigPharma in China
influencing the whole world